Testing effectiveness (Phase 2)Study completedNCT01127763What this trial is testingRAD001 Plus Carboplatin in Breast Cancer PatientsWho this might be right forBreast Cancer NYU Langone Health 25
Early research (Phase 1)Study completedNCT03544125What this trial is testingOlaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast CancerWho this might be right forAnatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor NegativeHER2/Neu Negative+3 more OHSU Knight Cancer Institute 3
Testing effectiveness (Phase 2)Ended earlyNCT04690855What this trial is testingEvaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast CancerWho this might be right forBreast CancerTriple Negative Breast Cancer Mylin A. Torres, MD 1
Large-scale testing (Phase 3)Study completedNCT04085276What this trial is testingToripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic TreatmentWho this might be right forTriple-Negative Breast Cancer Shanghai Junshi Bioscience Co., Ltd. 531
Testing effectiveness (Phase 2)Active Not RecruitingNCT06027268What this trial is testingPhase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast CancerWho this might be right forMetastatic Triple-Negative Breast Cancer Wake Forest University Health Sciences 36
Early research (Phase 1)UnknownNCT03151447What this trial is testingStereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast CancerWho this might be right forMetastatic Breast Cancer Fudan University 18
Large-scale testing (Phase 3)Study completedNCT00938652What this trial is testingA Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast CancerWho this might be right forBreast Cancer Sanofi 519
Testing effectiveness (Phase 2)UnknownNCT04913571What this trial is testingTislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II StudyWho this might be right forTriple Negative Breast Cancer Fudan University 265
Early research (Phase 1)Looking for participantsNCT07503808What this trial is testingIDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesWho this might be right forEsophageal Squamous Cell CarcinomaHigh Grade Serous Ovarian CancerHead and Neck Squamous Cell Carcinoma+5 more IDEAYA Biosciences 150
Testing effectiveness (Phase 2)Study completedNCT00633464What this trial is testingRandomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast CancerWho this might be right forTriple Negative Locally Advanced Non-resectable Breast CancerMetastatic Breast Cancer R-Pharm 79
Early research (Phase 1)WithdrawnNCT01333423What this trial is testingMaximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)Who this might be right forBreast Cancer M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT04148937What this trial is testingThe CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced CancerWho this might be right forAdvanced Cancer Eli Lilly and Company 52
Early research (Phase 1)Ended earlyNCT02419495What this trial is testingPhase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesWho this might be right forAdvanced Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+26 more M.D. Anderson Cancer Center 221
Testing effectiveness (Phase 2)Looking for participantsNCT06471205What this trial is testingBL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast CancerWho this might be right forTriple-negative Breast Cancer Sichuan Baili Pharmaceutical Co., Ltd. 52
Testing effectiveness (Phase 2)Ended earlyNCT04424641What this trial is testingA Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid TumorsWho this might be right forLocally Advanced or Metastatic Solid Tumor(s)Prostate CancerEsophageal Cancer+5 more Genmab 48
Testing effectiveness (Phase 2)Study completedNCT03872791What this trial is testingKN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast CancerWho this might be right forTriple-negative Breast Cancer Jiangsu Alphamab Biopharmaceuticals Co., Ltd 52
Testing effectiveness (Phase 2)Study completedNCT00733408What this trial is testingNab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast CancerWho this might be right forEstrogen Receptor-negative Breast CancerHER2-negative Breast CancerProgesterone Receptor-negative Breast Cancer+3 more University of Washington 59
Testing effectiveness (Phase 2)Ended earlyNCT02978716What this trial is testingTrilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)Who this might be right forTriple-Negative Breast NeoplasmsBreast NeoplasmBreast Cancer+1 more G1 Therapeutics, Inc. 102
Testing effectiveness (Phase 2)Active Not RecruitingNCT03330847What this trial is testingTo Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.Who this might be right forMetastatic Triple Negative Breast Cancer AstraZeneca 273
Testing effectiveness (Phase 2)Active Not RecruitingNCT04445844What this trial is testingINCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE StudyWho this might be right forAnatomic Stage IV Breast Cancer AJCC v8Locally Advanced Breast CarcinomaMetastatic Triple-Negative Breast Carcinoma+2 more Mridula George, MD 25